-
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening.
Cirigliano V, Ordonez E, Rueda L, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:460-4. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection.
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, Gerovassili A, Jin Y, Nicolaides KH, Cantor CR, Ding C.
Nat Med 2007;13:218-23. -
Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?
Gerovassili A, Garner C, Nicolaides KH, Thein SL, Rees DC.
Prenat Diagn 2007;27:104-10.